Targeting VEGF/VEGFR can inhibit angiogenesis in HNSCC, which include VEGF inhibitors (bevacizumab, ramucirumab) and VEGFR inhibitors (for example, sorafenib, anlotinib, apatinib, donafenib, sunitinib, cabozatinib, and vandetanib). This evidence concerns the gene KDR and head and neck squamous cell carcinoma.